Showing results (601-610 of 6,299) with videos related to
Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|February 25, 2009
Effect of antiobesity medications in patients with type 2 diabetes mellitusSouzana Choussein, Angeliki A Makri, Constantinos C Frangos, et al.Diabetes, Obesity & Metabolism|April 24, 2009
The scientific evidence: vildagliptin and the benefits of islet enhancementC MathieuDiabetes, Obesity & Metabolism|January 6, 2009
Insulin analogues: an example of applied medical scienceB Sheldon, D Russell-Jones, J WrightDiabetes, Obesity & Metabolism|January 6, 2009
The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetesR Krones, C Schütte, T HeiseDiabetes, Obesity & Metabolism|January 8, 2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyE Ferrannini, V Fonseca, B Zinman, et al.Diabetes, Obesity & Metabolism|December 18, 2008
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP studyJ-F Blicklé, N Hancu, M Piletic, et al.Diabetes, Obesity & Metabolism|October 18, 2008
Restoring a functional beta-cell mass in diabetesD Pipeleers, M Chintinne, B Denys, et al.Diabetes, Obesity & Metabolism|October 18, 2008
An examination of beta-cell function measures and their potential use for estimating beta-cell massS E Kahn, D B Carr, M V Faulenbach, et al.Diabetes, Obesity & Metabolism|October 18, 2008
Beta-cell function assessment from modelling of oral tests: an effective approachA Mari, E FerranniniDiabetes, Obesity & Metabolism|October 18, 2008
VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and diseaseM Freeby, R Goland, M Ichise, et al.Pageof 630